Navigation Links
Nephros Completes Bridge Financing and Announces Stockholder Rights Offering
Date:10/1/2010

arrants issued in the rights offering.  The term of the remaining Lambda Investors warrants will be increased to a five-year term, which is equal to the term of the warrants to be issued in the rights offering.

In connection with the proposed rights offering, Nephros has filed a registration statement on Form S-1 (File No. 333-169728), as may be amended, with the Securities and Exchange Commission (the "SEC"), which registration statement has not yet become effective.  The securities offered in the rights offering may not be sold, nor may offers to buy be accepted, prior to the time the registration statement becomes effective.  This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities, in any state in which such offer, solicitation or sale would be unlawful prior to their registration or qualification under the securities laws of any such state.  The securities may only be offered by means of a prospectus, copies of which may be obtained (when available) free of charge at the website maintained by the SEC at www.sec.gov or by contacting the Company's Chief Financial Officer at (201) 343-5202.  The prospectus will contain important information about the rights offering, and the company's stockholders are urged to read the prospectus carefully when available.

About Nephros, Inc.

Nephros, Inc., headquartered in River Edge, New Jersey, is a medical device company developing and marketing filtration products for therapeutic applications, infection control, and water purification.

The Nephros hemodiafiltration ("HDF") system is designed to improve the quality of life for the End-Stage Renal Disease (ESRD) patient while addressing the critical financial and clinical needs of the care provider.  ESRD is a disease state characterized by the irreversible loss of kidney function.  T
'/>"/>

SOURCE Nephros, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Nephros Reports 2010 Second Quarter Financial Results
2. Nephros Receives Formal Response from FDA for 510(k) Application for Hemodiafiltration System
3. Nephros and AmeriWater Announce Dual Stage Ultrafilters to be a Standard Component of MRO Series Water Treatment Systems
4. Nephros Reports 2010 First Quarter Financial Results
5. Nephros Signs Development Agreement with STERIS
6. Nephros Signs Canadian Distribution Agreement with Bellco Health Care Inc.
7. Nephros Reports 2009 Third Quarter Financial Results
8. Nephros Completes Pivotal U.S. Clinical Trial for its Hemodiafiltration Products
9. Tigris Pharmaceuticals, Inc. Completes $6.5 Million Private Placement
10. Johnson & Johnson Completes Acquisition of Micrus Endovascular
11. Endo Pharmaceuticals Successfully Completes Tender Offer for Shares of Penwest Pharmaceuticals
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/16/2014)... , Oct. 16, 2014 The ... guidance on the application of single-use, or ... pharmaceutical and biopharmaceutical products with the publication ... Application of Single-Use Systems in Pharmaceutical ... described as single-use systems (SUS) or single-use ...
(Date:10/16/2014)... , Oct. 16, 2014 Curtis & ... under 3 weeks away from hosting their co-located ... Oral Drug Formulation Innovations Summit taking place ... San Diego, CA. November,s events ... organizations in streamlining the bioequivalence testing process, as well ...
(Date:10/16/2014)... PHILADELPHIA , Oct. 16, 2014 Ninety ... (ALL) who had relapsed multiple times or failed to ... an investigational personalized cellular therapy, CTL019, developed at the ... The results published today in The ... new data, which builds on preliminary findings presented at ...
Breaking Medicine Technology:PDA Offers Help in Applying Single-Use Systems to Bio/Pharma Operations 2Simplifying the Bioequivalence Testing Process and Optimizing Oral Formulation Development via Unifying the Global Life Science Community this November in San Diego 2Personalized Cellular Therapy Achieves Complete Remission in 90 Percent of Acute Lymphoblastic Leukemia Patients Studied 2Personalized Cellular Therapy Achieves Complete Remission in 90 Percent of Acute Lymphoblastic Leukemia Patients Studied 3Personalized Cellular Therapy Achieves Complete Remission in 90 Percent of Acute Lymphoblastic Leukemia Patients Studied 4Personalized Cellular Therapy Achieves Complete Remission in 90 Percent of Acute Lymphoblastic Leukemia Patients Studied 5Personalized Cellular Therapy Achieves Complete Remission in 90 Percent of Acute Lymphoblastic Leukemia Patients Studied 6
... Health Corp. (Nasdaq: WBMD ) today announced the ... amount of 2.50% Convertible Notes due 2018 (including $50 million ... full of the initial purchaser,s over-allotment option).  The notes were ... under the Securities Act of 1933.   The ...
... NEW YORK, Jan. 11, 2011 Reportlinker.com ... is available in its catalogue: ... Price cuts set to negatively impact both ... http://www.reportlinker.com/p0360216/Spain-Pharmaceutical-Market-Overview – Price-cuts-set-to-negatively-impact-both-branded-and-generics-companies.html ...
Cached Medicine Technology:WebMD Closes Offering of 2.50% Convertible Notes Due 2018 2Reportlinker Adds Spain Pharmaceutical Market Overview - Price cuts set to negatively impact both branded and generics companies 2
(Date:10/18/2014)... New York, New York (PRWEB) October 18, 2014 ... allege the IUD caused women to sustain serious injuries ... the uterus continue to mount in U.S. courts, Bernstein ... issued by the U.S. Judicial Panel on Multidistrict Litigation ... are now pending in the multidistrict litigation underway in ...
(Date:10/18/2014)... One major trend upcoming in this market is ... making efforts to encourage people to donate organs. The ... process more transparent and easy. , Analysts forecast the ... at a CAGR of 16.85 percent over the period ... drivers in the market is an increase in the ...
(Date:10/18/2014)... New York, New York (PRWEB) October 18, 2014 ... continue to mount in a mass tort litigation ... Pleas, Bernstein Liebhard LLP reports. According to court ... in the proceeding on behalf of Risperdal patients ... gynecomastia (male breast growth), due to their use ...
(Date:10/18/2014)... Oct. 18, 2014 (HealthDay News) -- Even determined dieters ... of healthy foods nearby, researchers say. Their new ... had metabolic syndrome (a combination of risk factors that ... And, all were told by their doctors to make ... The participants were involved in a clinical trial ...
(Date:10/18/2014)... is known to most people, ASP.NET hosting is a ... Cheap Hosting USA has compared many professional web ASP.NET ... JustHost are among the most reliable companies in the ... a good ASP.NET supplier. Actually, these companies have outperformed ... customer support. People can get the best web hosting ...
Breaking Medicine News(10 mins):Health News:Mirena Lawsuit Filings Grow, as Claims Pending in Federal Litigation Exceed 1,000, Bernstein Liebhard LLP Reports 2Health News:Mirena Lawsuit Filings Grow, as Claims Pending in Federal Litigation Exceed 1,000, Bernstein Liebhard LLP Reports 3Health News:Mirena Lawsuit Filings Grow, as Claims Pending in Federal Litigation Exceed 1,000, Bernstein Liebhard LLP Reports 4Health News:Organ Preservation Solutions Market to Grow at 16.85% CAGR to 2018 Forecast a New Research Report at Sandlerresearch.org 2Health News:Organ Preservation Solutions Market to Grow at 16.85% CAGR to 2018 Forecast a New Research Report at Sandlerresearch.org 3Health News:Organ Preservation Solutions Market to Grow at 16.85% CAGR to 2018 Forecast a New Research Report at Sandlerresearch.org 4Health News:Risperdal Lawsuits Mount, as Claims in Pennsylvania Litigation Near 900, Bernstein Liebhard LLP Reports 2Health News:Risperdal Lawsuits Mount, as Claims in Pennsylvania Litigation Near 900, Bernstein Liebhard LLP Reports 3Health News:Dieters May Be Thwarted by Absence of Healthy Foods 2
... News) -- Media multitasking -- the use of more than ... -- may have some positive effects, a new study suggests. ... which is especially common in young people and could include ... or social networking -- have received widespread publicity. But ...
... CINCINNATINew research at the University of Cincinnati (UC) ... a complex process that can provide cells with ... circumstances autophagy can protect tumor cells from chemotherapy, ... time in a hidden, dormant, metastatic state. ...
... , SUNDAY, April 15 (HealthDay News) -- A ... regions linked to fractures and osteoporosis. Variations in ... bone-weakening disease, the investigators reported in a new study published ... . The study authors added that their findings could ...
... appear to be rising, especially among high school students, ... is alarming and indicates more coaches and athletic trainers ... the game, according to researchers based at the University ... the number of football-related brain injuries with permanent disability ...
... Cancer is much more likely in the elderly than the ... disease and the often-toxic side effects of treatment. But ... The University of Texas Health Science Center at San Antonio shows ... younger patients can be used to help the elderly, with less ...
... , FRIDAY, April 13 (HealthDay News) -- In a new study ... of sun damage, middle schoolers showed evidence of levels of UV ... Not only can the technology spot who is most vulnerable ... noted, but it could also be used as a powerful deterrent ...
Cached Medicine News:Health News:Media Multitasking Might Have Mental Upside 2Health News:Specific inhibition of autophagy may represent a new concept for treatment of kidney cancer 2Health News:Certain Genetic Regions May Be Tied to Osteoporosis 2Health News:Football-related catastrophic brain injuries on the rise 2Health News:Football-related catastrophic brain injuries on the rise 3Health News:Immunotherapy for elderly cancer patients finds new promise in drug combination 2Health News:Immunotherapy for elderly cancer patients finds new promise in drug combination 3Health News:Even Young Teens Show Signs of Sun Damage 2Health News:Even Young Teens Show Signs of Sun Damage 3Health News:Even Young Teens Show Signs of Sun Damage 4
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: